Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- EmergingMarketsllc.com: Emerging Equity Alerts.
- M2 PRESSWIRE-16 June 2006-Emerging Markets Consulting, LLC.: EmergingMarketsllc.com: Emerging Equity AlertsC1994-2006 M2 COMMUNICATIONS LTD RDATE:16062006 Orlando, FL - Stocks gaining traction in yesterday's trading are Millennium Pharmaceuticals, Inc., (NASDAQ: MLNM), Encysive Pharmaceuticals, Inc., (NASDAQ: ENCY), Discovery Laboratories, Inc., (NASDAQ:...
- Research articles 2006-06-16
- "Stocks on the Rise".
- M2 PRESSWIRE-15 June 2005-WallStreetGrapevine: "Stocks on the Rise"C1994-2005 M2 COMMUNICATIONS LTD RDATE:15062005 Wall Street, NYC - Today, wallstreetgrapevine.com, named; FacePrint Global Solutions, Inc. (OTC BB: FCPG), Aastrom Biosciences, Inc. (Nasdaq SC: ASTM), Millennium Pharmaceuticals, Inc. (Nasdaq NM: MLNM), and Abgenix...
- Research articles 2005-06-15
- Zacks.com Announces That Nadine Wong Highlights the Following Stock: Millenium Pharmaceuticals
- CHICAGO -- Nadine Wong is raising sales and earnings estimates for one cancer company, and explains why she expects 2005 to turn to profitability with upside from a massive pipeline. Read about Millenium Pharmaceuticals (NASDAQ:MLNM). Nadine Wong is editor of the Biotech Stock Report newsletter. Click here for the full...
- Research articles 2004-09-28
- Millennium acquires rights to proteasome inhibitors and related synthesis techonology - agreement to augment company's proteasome inhibitor program-.(Millennium Pharmaceuticals Inc.)
- Millennium Pharmaceuticals, Inc. (Cambridge, MA) today announced it has signed a research agreement with Harvard University and Professor E.J. Corey for a family of proteasome inhibitors and a related chemical synthesis process. Millennium intends to utilize the agreement to enhance the Company's ongoing efforts to develop...
- Research articles 2004-05-01
- Cambridge, Mass.-Based Pharmaceutical Firm Expects Big Sales for Cancer Drug.
- By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Jan. 13--Millennium Pharmaceuticals Inc. yesterday said it expects to sell up to $160 million worth of its Velcade cancer drug this year, nearly three times its 2003 sales, and said layoffs and...
- Research articles 2004-01-13
- The International Myeloma Foundation Says Newly Diagnosed Patients Could Benefit from FDA "Priority Review" of VELCADE® for Front-Line Use
- NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said the FDA decision granting "priority review" for VELCADE[R] in newly diagnosed myeloma recognizes the benefits of powerful new therapies and the need...
- Research articles 2008-02-04
- FDA Approves Millenium's VELCADE -bortezomib- for Use in Second-Line Multiple Myeloma; International Myeloma Foundation Applauds Approval of New Therapy
- NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF, the country's oldest and largest myeloma organization, applauds the U.S. Food and Drug Administration's FDA approval of VELCADER. This approval expands the label to include the treatment of multiple myeloma patients who have received at least one prior therapy. The approval...
- Research articles 2005-03-29
- Gemin X's Pan-Bcl-2 Antagonist GX15-070 Permits Rational Combination with Velcade in Mantle Cell Lymphoma
- Data Presented in an Oral Presentation at American Society of Hematology Annual Meeting
- Research articles 2006-12-13
- Millennium overhauls operations. (Markets: Life Sciences).(Millennium Pharmaceuticals Inc)
- MILLENNIUM Pharmaceuticals Inc. will trim its global work force by 26 percent and consolidate operations under a restructuring plan for profitability by 2006. The move comes on the heels of a critical Food and Drug Administration FDA approval for MILLENNIUM Pharmaceuticals Inc. will trim...
- Research articles 2003-06-16
- VELCADE (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients With Previously Untreated Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. displays the encouraging data from two ongoing phases II investigator-sponsored clinical trials examining the potential role of VELCADE in patients with previously untreated multiple myeloma. The trials are examining VELCADE alone and in combination with standard treatments, including dexamethasone and doxorubicin.
- White papers
- Millennium Files Supplemental New Drug Application for VELCADE (bortezomib) for Injection for the Treatment of Patients With Second-Line Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the submission of the Company's supplemental New Drug Application sNDA to the U.S. Food and Drug Administration FDA for VELCADE for the treatment of patients with multiple myeloma who have received at least one prior therapy, a patient population of approximately 22,000 in...
- White papers
- FDA Grants VELCADE (Bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma
- In this article Millennium Pharmaceuticals, Inc. informs that the Food and Drug Administration FDA has granted VELCADE fast track designation for relapsed and refractory mantle cell lymphoma, an aggressive form of non-Hodgkin's lymphoma NHL which accounts for approximately six percent of all lymphomas. Currently, VELCADE is being evaluated as a...
- White papers
- FDA Accepts sNDA Filing With Priority Review for VELCADE (Bbortezomib) for Injection to Treat Second-Line Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. informs that the U.S. Food and Drug Administration FDA accepted for review the Company's supplemental New Drug Application sNDA and granted Priority Review designation for VELCADE for the treatment of patients with multiple myeloma who have received at least one prior therapy. The submission...
- White papers
- VELCADE (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs about the approval from the U.S. Food and Drug Administration FDA to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is...
- White papers 2003-05-15
- Final Phase II Data Presented From the VELCADE (Bortezomib) for Injection SUMMIT Trial in Patients With Advanced Stage Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses their final results from the phase II SUMMIT trial (previously known as 025) for its investigational cancer drug VELCADE in patients with relapsed and refractory multiple myeloma that were progressing on their last prior therapy. The findings indicated that a majority of patients...
- White papers 2002-12-09
- Millennium Announces Assignment of Medicare Code for Velcade (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that the Center for Medicare and Medicaid Services CMS has qualified VELCADE for pass-through status and assigned it to a Healthcare Common Procedure Coding System HCPCS whereby hospitals may obtain reimbursement for VELCADE under the hospital outpatient prospective payment system OPPS effective October...
- White papers 2003-09-26
- FDA Accepts for Review NDA Filing and Grants Priority Review for Velcade (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. reveals that the U.S. Food and Drug Administration FDA accepted for review and granted Priority Review designation of the Company's New Drug Application NDA for VELCADE for the treatment of relapsed and refractory multiple myeloma. Priority Review is granted by the FDA to an...
- White papers 2003-03-10
- Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE) 3.5MG Powder for Solution for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application MAA to the European Agency for the Evaluation of Medicinal Products EMEA for the approval of bortezomib VELCADE as a treatment for relapsed and refractory multiple myeloma. This application was submitted approximately one week...
- White papers 2003-02-04
- Millennium Submits New Drug Application for VELCADE (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a New Drug Application NDA with the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as...
- White papers 2003-01-22
- An Introduction to Proteasome Inhibition: A Unique Class of Drugs, A New Treatment Strategy
- This article focuses on VELCADE which is a novel drug candidate that may have broad applications in cancer. In January 2003, Millennium submitted a New Drug Application NDA to the U.S. Food and Drug Administration FDA for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma....
- White papers 2002-11-21
- << Previous
- page 1 of 2
- Next >>
